{
    "clinical_study": {
        "@rank": "4953", 
        "acronym": "CRIB", 
        "arm_group": {
            "arm_group_label": "Pharmacokinetic samples of mother, infant and umbilical cord", 
            "arm_group_type": "Experimental", 
            "description": "Pharmacokinetic (PK) samples will be taken from the mother, infant and umbilical cord at specific pre-defined time points.\nIncluded are mothers who decided to continue on, or to start treatment with, Certolizumab Pegol (CZP) for an approved indication with their treating physician prior to participation into this study. The mother is responsible for procuring her own supply of commercial CZP. The CZP dose and administration schedule will be as per the locally approved label."
        }, 
        "brief_summary": {
            "textblock": "The primary purpose is to assess whether there is transfer of Certolizumab Pegol (CZP) from\n      pregnant women receiving treatment with Cimzia\u00ae across the placenta to infants by evaluating\n      the concentration of CZP in the plasma of infants at birth."
        }, 
        "brief_title": "A Multicenter Study to Measure the Transfer of Cimzia\u00ae From Women to Infants Via the Placenta", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Axial Spondyloarthritis (AxSpA)", 
            "Non-radiographic Evidence-AxSpA", 
            "Ankylosing Spondylitis", 
            "Crohn's Disease", 
            "Psoriatic Arthritis", 
            "Rheumatoid Arthritis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Psoriatic", 
                "Arthritis, Rheumatoid", 
                "Crohn Disease", 
                "Spondylitis", 
                "Spondylitis, Ankylosing", 
                "Spondylarthritis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  An Institutional Review Board/Independent Ethics Committee (IRB/IEC) approved written\n             Informed Consent form for the maternal subject and written assent for her infant is\n             signed and dated by the subject or by the legal representative. Where applicable, the\n             written assent form for the infant is also signed and dated by the infant's father or\n             legal representative\n\n          -  Subject/legal representative is considered reliable and capable of adhering to the\n             protocol and visit schedule according to the judgment of the Investigator\n\n          -  Subject is female \u2265 18 years at the time of informed consent/assent\n\n          -  Subject is \u2265 30 weeks pregnant with a singleton or twins at the time of informed\n             consent/assent\n\n          -  Subject is being treated with Certolizumab Pegol (CZP) at a dose and administration\n             schedule per the locally approved label\n\n          -  Subject started, or decided to start, treatment with CZP independently from and prior\n             to being recruited for this study and in accordance with the treating physician\n\n          -  Subject expects to receive CZP until at least 35 days prior to expected delivery.\n             Additional criteria to be confirmed at Visit 2 (delivery)\n\n          -  Subject delivers a live born infant at or near term (\u2265 34  weeks gestation)\n\n          -  Subject received CZP within 35 days before delivery\n\n          -  Subject has not received contraindicated medication\n\n        Exclusion Criteria:\n\n          -  Subject has participated in a study of an investigational medicinal product (IMP) or\n             medical device within the previous 30 days or 5 half-lives (whichever is longer)\n             prior to Screening or is currently participating in another study of an IMP or\n             medical device - unless the study is UCB UP0016 or a registry study\n\n          -  Subject has any obstetrical or psychiatric condition, or she or her infant has any\n             medical condition that, in the opinion of the Investigator, could jeopardize or would\n             compromise the subject's ability to participate in this study or the outcome of the\n             pregnancy\n\n          -  Subject has history of chronic alcohol abuse or drug abuse during pregnancy\n\n          -  Subject has any pregnancy-related clinically significant abnormality noted on\n             obstetric ultrasound, or other imaging assessment, or the subject has significant\n             laboratory abnormalities during her pregnancy, as judged by the Investigator\n\n          -  Subject is taking a prohibited medication or has taken a prohibited medication\n\n          -  Subject has evidence of a condition suggesting chronic or acute uteroplacental\n             insufficiency such as intrauterine growth restriction, severe maternal hypertensive\n             disorders of pregnancy, or abruption\n\n          -  Subject has a documented history of primary or secondary antiphospholipid syndrome or\n             hypercoagulable state\n\n          -  Subject has received treatment with any biological therapeutic agent, including\n             anti-Tumor Necrosis Factors (TNFs) other than CZP, during pregnancy\n\n          -  Subject has previously participated in this study\n\n          -  Subject has a positive or indeterminate QuantiFERON\u00ae-TB GOLD In Tube test at\n             Screening. In case of indeterminate result, a retest is allowed if time permits; 2\n             results of indeterminate require exclusion of the subject. Tuberculosis (TB) test\n             results that have been obtained within the previous 60 days prior to Screening are\n             acceptable (QuantiFERON\u00ae-TB GOLD or Purified Protein Derivative [PPD] test)\n\n          -  Subject has known TB infection, at high risk of acquiring TB infection or latent TB\n             infection"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02019602", 
            "org_study_id": "UP0017", 
            "secondary_id": "2013-003812-30"
        }, 
        "intervention": [
            {
                "arm_group_label": "Pharmacokinetic samples of mother, infant and umbilical cord", 
                "description": "A blood sample from the mother will be taken within 24 hours before/after the delivery.", 
                "intervention_name": "Blood draw from mother", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Pharmacokinetic samples of mother, infant and umbilical cord", 
                "description": "Blood samples from the infant will be taken within 24 hours after birth, at Week 4 and at Week 8.", 
                "intervention_name": "Blood draw from infant", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Pharmacokinetic samples of mother, infant and umbilical cord", 
                "description": "A blood sample from the umbilical cord will be taken directly (within 1 hour ) after delivery.", 
                "intervention_name": "Blood draw from umbilical cord", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Pharmacokinetic samples of mother, infant and umbilical cord", 
                "description": "Mothers who decided to continue on, or to start treatment with, CZP for an approved indication with their treating physician prior to participation into this study. The mother is responsible for procuring her own supply of commercial CZP. The CZP dose and administration schedule will be as per the locally approved label.", 
                "intervention_name": "Certolizumab Pegol", 
                "intervention_type": "Biological", 
                "other_name": "Cimzia\u00ae"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Immunoglobulin Fab Fragments"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Cimzia\u00ae", 
            "CZP", 
            "Placental transfer", 
            "Autoimmune diseases and pregnancy"
        ], 
        "lastchanged_date": "March 28, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }, 
                    "name": "1"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bern", 
                        "country": "Switzerland"
                    }, 
                    "name": "20"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Switzerland"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multicenter Postmarketing Study to Evaluate the Placental Transfer of Certolizumab Pegol in Pregnant Women Receiving Treatment With Cimzia\u00ae (Certolizumab Pegol) Phase 1b (Clinical Pharmacology)", 
        "overall_contact": {
            "last_name": "UCB Clinical Trial Call Center", 
            "phone": "+1 877 822 9493"
        }, 
        "overall_official": {
            "affiliation": "+1 877 822 9493 (UCB)", 
            "last_name": "UCB Clinical Trial Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Switzerland: Ethikkommission", 
                "Germany: Paul-Ehrlich-Institut", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The plasma concentration of Certolizumab Pegol (CZP) in the infant at birth", 
            "safety_issue": "No", 
            "time_frame": "Blood samples will be taken within 24 hours after birth from the infants"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02019602"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "The plasma concentration of Certolizumab Pegol (CZP) in the mother at delivery", 
                "safety_issue": "No", 
                "time_frame": "Blood samples will be taken within 24 hours before/after delivery from the mothers"
            }, 
            {
                "measure": "The ratio of plasma concentration of Certolizumab Pegol (CZP) between the infant and mother at birth", 
                "safety_issue": "No", 
                "time_frame": "Blood samples will be taken within 24 hours before/after delivery from the mothers and within 24 hours after birth from the infants"
            }, 
            {
                "measure": "The plasma concentration of Certolizumab Pegol (CZP) in the umbilical cord at birth", 
                "safety_issue": "No", 
                "time_frame": "Blood samples will be taken directly after delivery (within <= 1 hour) from the umbilical cord"
            }, 
            {
                "measure": "The plasma concentration of anti-CZP antibodies in the mother at delivery", 
                "safety_issue": "No", 
                "time_frame": "Blood samples will be taken within 24 hours before/after delivery from the mothers"
            }, 
            {
                "measure": "The plasma concentration of anti-CZP antibodies in the umbilical cord at birth", 
                "safety_issue": "No", 
                "time_frame": "Blood samples will be taken directly after delivery (within <= 1 hour) from the umbilical cord"
            }
        ], 
        "source": "UCB, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "UCB BIOSCIENCES, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}